文献速递心血管MR

心脏磁共振评估的局灶性与弥漫性纤维化与射血分数保留的心力衰竭临床结局的关系

Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
PubMed 文献 · JACC Cardiovasc Imaging · 2019-02-13

前瞻性观察研究纳入140例年龄性别相近者(HFpEF 96例,对照44例),用心脏磁共振晚期钆增强和T1 mapping评估纤维化。HFpEF患者局灶性和弥漫性纤维化均更常见,iECV是HFpEF不良结局的独立预测因子。

要点

  • HFpEF患者局灶性纤维化更常见(49例 vs 对照3例),弥漫性纤维化iECV更高(13.7 vs 10.9 ml/m2)。
  • iECV是HFpEF不良结局的独立预测因子(HR 1.689,95%CI 1.141-2.501,p=0.009)。
  • LGE显示的心肌梗死仅在单变量分析中预测结局,多变量分析中不独立。

核心结论

  • HFpEF患者局灶性和弥漫性心肌纤维化均比年龄性别相近的对照更常见,iECV与心室/左房重构和肾功能不全显著相关,且是HFpEF不良结局的独立预测因子。

研究设计与样本

  • 前瞻性观察研究,纳入140例年龄性别相近的受试者(HFpEF 96例,对照44例,73±8岁,49%男性),均接受心脏磁共振晚期钆增强成像和T1 mapping计算经体表面积标化的心肌细胞外容积(iECV)。

关键影像表现/征象

  • HFpEF患者同心圆重构更明显且舒张功能更差。
  • HFpEF患者局灶性纤维化更常见(总体49例,其中心肌梗死17例、非缺血性36例、混合型4例),对照组仅3例。
  • HFpEF患者弥漫性纤维化iECV高于对照(13.7±4.4 ml/m2 vs 10.9±2.8 ml/m2,p<0.0001)。

诊断标准与关键数值

  • iECV多变量分析为结局独立预测因子(HR 1.689,95%CI 1.141-2.501,p=0.009)。
  • E/E'比值多变量分析为结局独立预测因子(HR 1.716,95%CI 1.191-2.472,p=0.004)。
  • 既往HF住院多变量分析为结局独立预测因子(HR 2.537,95%CI 1.090-5.902,p=0.031)。
  • LGE显示的心肌梗死仅在单变量分析中预测结局。

临床应用与阅片要点

  • iECV与右室舒张末期容积指数相关(r=0.456,p<0.0001)。
  • iECV与左室质量/容积比相关(r=0.348,p=0.001)。
  • iECV与肌酐相关(r=0.271,p=0.009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study sought to assess the presence and extent of focal and diffuse fibrosis in heart failure in patients with preserved ejection fraction (HFpEF) compared to asymptomatic control subjects, and the relationship of fibrosis to clinical outcome.

BACKGROUND: Myocardial fibrosis has been implicated in the pathophysiology of HFpEF.

METHODS: In this prospective, observational study, 140 subjects of similar age and sex (HFpEF: n = 96; control subjects: n = 44; 73 ± 8 years of age; 49% males) underwent cardiac magnetic resonance imaging. Late gadolinium-enhanced (LGE) imaging and T1 mapping to calculate myocardial extracellular volume indexed to body surface area (iECV) were used to assess fibrosis.

RESULTS: Patients with HFpEF had more concentric remodeling and worse diastolic function. Focal fibrosis was more frequent in HFpEF subjects (overall: n = 49; infarction: n = 17; nonischemic cases: n = 36; mixed patterns: n = 4) than in control subjects (overall: n = 3). Diffuse fibrosis was also greater in HFpEF subjects than control subjects (iECV: 13.7 ± 4.4 ml/m2 versus 10.9 ± 2.8 ml/m2; p < 0.0001). During median follow-up (1,429 days), there were 42 composite events (14 deaths; 28 heart failure hospitalizations) in cases of HFpEF. Myocardial infarction revealed on LGE imaging was a predictor of outcomes on univariate analysis only. With multivariate analysis, iECV (hazard ratio [HR]: 1.689; 95% confidence interval [CI]: 1.141 to 2.501; p = 0.009) was an independent predictor of outcome along with mitral peak velocity of early filling (E)-to-early diastolic mitral annular velocity (E') (E/E') ratio (HR: 1.716; 95% CI: 1.191 to 2.472; p = 0.004) and prior HF hospitalization (HR: 2.537; 95% CI: 1.090 to 5.902; p = 0.031). iECV was also significantly associated with ventricular/left atrial remodeling and renal dysfunction: right ventricular end-diastolic volume indexed (r = 0.456; p < 0.0001), left ventricular mass/volume (r = 0.348; p = 0.001), maximal left atrial volume indexed (r = 0. 269; p = 0.009), and creatinine (r = 0.271; p = 0.009).

CONCLUSIONS: Both focal and diffuse myocardial fibrosis are more prevalent in HFpEF subjects than in control subjects of similar age and sex. iECV significantly correlates with indices of ventricular/left atrial remodeling and renal dysfunction and is an independent predictor of adverse outcome in HFpEF. (Developing Imaging And plasMa biOmarkers iN Describing Heart Failure With Preserved Ejection Fraction [DIAMONDHFpEF]; NCT03050593).

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Kanagala P, Cheng ASH, Singh A, et al. Relationship Between Focal and Diffuse Fibrosis Assessed by CMR and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Cardiovasc Imaging. 2019. PMID: 30772227. doi:10.1016/j.jcmg.2018.11.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。